Clinical Trials Directory

Trials / Completed

CompletedNCT02068300

The Role of 1.5-anhydro-D-glucitol as Clinical Biomarkers of Hypoglycemia in Patients With Diabetes

1,5-Anhydro-D-Glucitol Can Reflect Hypoglycemia in Patients With Well Controlled Type 2 Diabetes

Status
Completed
Phase
Study type
Observational
Enrollment
51 (actual)
Sponsor
Seoul National University Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the usefulness of plasma 1,5-anhydro-D-glucitol (1,5-AG) as a novel surrogate marker of hypoglycemia

Detailed description

We enrolled well controlled diabetes patients who had hypoglycemic event at least one time more. All patients assess the risk of severe hypoglycemia and hypoglycemic unawareness using hypoglycemic awareness questionnaires (HYPO score). The patients who are treated with insulin agent were inserted sensor of continuous glucose monitoring systems under the skin during three days. We were analysed the correlation between 1,5-anhydro-D-glucitol and HYPO score.

Conditions

Timeline

Start date
2013-10-01
Primary completion
2016-02-01
Completion
2016-03-01
First posted
2014-02-21
Last updated
2016-04-15

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02068300. Inclusion in this directory is not an endorsement.

The Role of 1.5-anhydro-D-glucitol as Clinical Biomarkers of Hypoglycemia in Patients With Diabetes (NCT02068300) · Clinical Trials Directory